MSME (Udyam registered) Ministry of MSME
- Category
- Micro (2024-25)
- Udyam number
- UDYAM-MH-33-0128403
Kdpress Pharmaceuticals Private Limited
Kdpress Pharmaceuticals Private Limited - home appliances in Dombivali East, Maharashtra, India. Directors, charges & compliance details.
Revenue · FY 2025
₹1.17 Cr
▲ 242% YoY
Net profit · FY 2025
₹9 Lakh
Net margin 7.7%
EBITDA · FY 2025
₹11.98 Lakh
EBITDA margin 10.2%
Authorised capital
₹1 Lakh
Registered with MCA
Paid-up capital
₹1 Lakh
Issued & subscribed
Open charges
₹10 Lakh
Secured borrowings
Company age
6 yrs
Est. 2020
Directors on board
2
As per MCA filings
About Kdpress Pharmaceuticals Private Limited
Data last updated:
Kdpress Pharmaceuticals Private Limited is a private limited company based in Dombivali East, Maharashtra, India. It operates in the retail trade segment of the home appliances and consumer durables sector. It was incorporated on 04 March 2020 and has been in existence for over 6 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U52100MH2020PTC338588.
The company has an authorised share capital of ₹1 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors Dilip Singh Karan Singh Rao and Karan Singh Rao.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Shop No 01 Om Saikrupa Moti Nagar Khalcha Pada, Dombivali East, Maharashtra, India – 421201.
As per the financials filed for FY 2025, the company reported a revenue of ₹1.17 Cr, reflecting significant growth compared to the previous year. For the same year it recorded a net profit of ₹9 Lakh (net margin 7.7%) and EBITDA of ₹11.98 Lakh (EBITDA margin 10.2%). Revenue has grown at a compounded annual rate (CAGR) of 249% over three years.
As per MCA filings, the company has open charges of ₹10 Lakh on record.
Kdpress Pharmaceuticals Private Limited is registered as a micro enterprise under the Udyam registration framework (Reg. No. UDYAM-MH-33-0128403).
Company Details of Kdpress Pharmaceuticals Private Limited
CIN U52100MH2020PTC338588
Registration Number 338588
Incorporation Date 04 March 2020
ROC Mumbai
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2025
MSME Classification Micro
Udyam Registration UDYAM-MH-33-0128403
Recognitions & Rankings of Kdpress Pharmaceuticals
Contact Details
- EmailLocked
- TelephoneLocked
- WebsiteLocked
- Social MediaLocked
- Registered AddressShop No 01 Om Saikrupa Moti Nagar Khalcha Pada, Dombivali East, Maharashtra, India – 421201
- IndustryHome Appliances, Retailers, Non Specialized Stores
Comprehensive company report
Kdpress Pharmaceuticals Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Business Activity of Kdpress Pharmaceuticals Private Limited
The main business activity of Kdpress Pharmaceuticals is manufacturing. In detail, this covers manufacture of basic pharmaceutical products and pharmaceutical preparations.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | 21 | Manufacture of basic pharmaceutical products and pharmaceutical preparations | Locked |
Premium access
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Kdpress Pharmaceuticals Private Limited FY 2025 filings available
Kdpress Pharmaceuticals Private Limited reported revenue of ₹1.17 Cr (up 242% YoY) for FY 2025.
Revenue · FY 2025
₹1.17 Cr ▲ 242%
Net profit · FY 2025
₹9 Lakh margin 7.7%
EBITDA · FY 2025
₹11.98 Lakh margin 10.2%
Compounded Annual Growth Rate (CAGR) of Kdpress Pharmaceuticals Private Limited
Revenue CAGR growth
1 year
▲ 242%
3 years · compounded
▲ 249%
EBITDA CAGR growth
1 year
▲ 424%
3 years · compounded
▲ 252%
Revenue has grown at a compounded annual rate (CAGR) of 249% over three years, including 242% growth in the latest year. EBITDA rose 424% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Kdpress Pharmaceuticals Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹11.98 Lakh | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹9 Lakh | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Kdpress Pharmaceuticals Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 10.2% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 7.7% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Kdpress Pharmaceuticals are in the company report.
Premium access
Financial statements from FY 2020
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Board of Directors of Kdpress Pharmaceuticals Private Limited
Kdpress Pharmaceuticals has 2 current directors and 1 former director. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Dilip Singh Karan Singh Rao | Director | 05 Feb 2021 | 5 Years 8 Months | Current |
| Karan Singh Rao | Director | 04 Mar 2020 | 6 Years 7 Months | Current |
Peer Comparison of Kdpress Pharmaceuticals Private Limited
Kdpress Pharmaceuticals Private Limited is compared with the companies closest to it by revenue in the Pharma industry (Pharma Retail and Distribution, Pharmaceuticals). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Walsun Life Science Private Limited | ₹1.18 Cr (FY 2025) | •••• | •••• | 135.0% | •••• | Pune, Maharashtra, India |
| Zywie Pharmaceuticals Private Limited | ₹1.17 Cr (FY 2019) | •••• | •••• | 552.0% | •••• | Hyderabad, Telangana, India |
| Ameshia Pharmaceuticals Private Limited | ₹1.17 Cr (FY 2025) | •••• | •••• | 14.0% | •••• | Hyderabad, Telangana, India |
| Sweyer Pharmaceuticals Private Limited | ₹1.17 Cr (FY 2025) | •••• | •••• | 30.0% | •••• | Kozhikode, Kerala, India |
| Syndrome Pharmaceuticals Private Limited | ₹1.17 Cr (FY 2025) | •••• | •••• | -8.0% | •••• | Patna, Bihar, India |
| Kdpress Pharmaceuticals Private Limited this company | ₹1.17 Cr (FY 2025) | •••• | •••• | 242.0% | •••• | Dombivali East, Maharashtra, India |
| Zeus Drugs Limited | ₹1.17 Cr (FY 2025) | •••• | •••• | -3.0% | •••• | New Delhi, Delhi, India |
| Trident Pharmaceuticals Pvt Ltd | ₹1.17 Cr (FY 2025) | •••• | •••• | -7.0% | •••• | Hyderabad, Telangana, India |
| Doshi Healthcare Private Limited | ₹1.17 Cr (FY 2025) | •••• | •••• | •••• | Mumbai, Maharashtra, India | |
| Swastika Wellness Private Limited | ₹1.17 Cr (FY 2022) | •••• | •••• | 461.0% | •••• | Delhi, India |
| RTF Medicals Private Limited | ₹1.17 Cr (FY 2024) | •••• | •••• | 132.0% | •••• | Thiruvananthapuram, Kerala, India |
Peers are the five companies nearest above and the five nearest below Kdpress Pharmaceuticals by revenue in the Pharma industry (Pharma Retail and Distribution, Pharmaceuticals), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Charges & Borrowings of Kdpress Pharmaceuticals Private Limited
Open charges
₹10 Lakh
Satisfied charges
None
Breakdown by lending institutions
Latest charge details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 27 Mar 2025 | Others | ₹10 Lakh | Open |
Total charge records: 1 View all charges
Employees and EPFO Compliance at Kdpress Pharmaceuticals Private Limited
Employment history and EPFO contributions of people linked to Kdpress Pharmaceuticals.
Premium access
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Kdpress Pharmaceuticals Private Limited
Kdpress Pharmaceuticals Private Limited has 4 board changes on record since 2020: 3 appointments and 1 cessation. The latest: Ajaysingh Karansingh Rao ceased to be Director on 25 Feb 2021.
AGM
Kdpress Pharmaceuticals Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Filing
Kdpress Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai.
Charges
A charge with Others amounted to Rs. 10.00 Lakh with Charge ID 101083624 was registered on 27 Mar 2025.
Ceased
Ajaysingh Karansingh Rao ceased to be Director.
Appointed
Dilip Singh Karan Singh Rao was appointed as Director.
Appointed
Ajaysingh Karansingh Rao was appointed as Director.
Appointed
Karan Singh Rao was appointed as Director.
Incorporation
04 Mar 2020
Kdpress Pharmaceuticals Private Limited was registered on 04 Mar 2020 with Roc Mumbai & aged 6 years 7 months as per MCA records.
Credit Ratings, Litigation & Regulatory Alerts for Kdpress Pharmaceuticals Private Limited
Premium access
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Kdpress Pharmaceuticals Private Limited
Premium access
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Kdpress Pharmaceuticals Private Limited
Premium access
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Kdpress Pharmaceuticals Private Limited
Premium access
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Kdpress Pharmaceuticals Private Limited
Premium access
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kdpress Pharmaceuticals Private Limited
Kdpress Pharmaceuticals is an active private limited company based in Dombivali East, Maharashtra, India. The company works in retailers, within the home appliances industry. It was incorporated on 04 March 2020 (6+ years old) and is registered under CIN U52100MH2020PTC338588.
Kdpress Pharmaceuticals reported revenue of ₹1.17 Cr for FY 2025 (up 242% YoY).
Kdpress Pharmaceuticals has 2 current directors:
- Dilip Singh Karan Singh Rao - Director
- Karan Singh Rao - Director
Kdpress Pharmaceuticals reported a net profit of ₹9 Lakh (net margin 7.7%) and EBITDA of ₹11.98 Lakh (EBITDA margin 10.2%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Kdpress Pharmaceuticals is 249% over three years. In the latest year (FY 2025) revenue rose 242%. CAGR is the steady yearly rate that links the first and the last year.
The CIN (Corporate Identification Number) of Kdpress Pharmaceuticals is U52100MH2020PTC338588. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Kdpress Pharmaceuticals was incorporated on 04 March 2020, making it 6+ years old. It is registered with the Registrar of Companies, Mumbai.
The peers of Kdpress Pharmaceuticals by revenue are Walsun Life Science Private Limited, Zywie Pharmaceuticals Private Limited, Ameshia Pharmaceuticals Private Limited, Sweyer Pharmaceuticals Private Limited, Syndrome Pharmaceuticals Private Limited and 5 more, all in the Pharma industry (Pharma Retail and Distribution, Pharmaceuticals).
Ajaysingh Karansingh Rao ceased to be Director on 25 Feb 2021. Dilip Singh Karan Singh Rao was appointed as Director on 05 Feb 2021. Ajaysingh Karansingh Rao was appointed as Director on 04 Mar 2020. Kdpress Pharmaceuticals has 4 board changes on record in total.
Yes, Kdpress Pharmaceuticals is registered as a micro enterprise under Udyam registration (number: UDYAM-MH-33-0128403).
The registered office of Kdpress Pharmaceuticals is at Shop No 01 Om Saikrupa Moti Nagar Khalcha Pada, Dombivali East, Maharashtra, India – 421201.